Sorry. You can not access the page.

The page pro.biontech.com is not accessible from your location. You have been redirected to our corporate website for more information and resources.

See our Annual Report for the year 2025 for detailed updates on our pipeline candidates.

Pipeline

Breakthrough technologies to revolutionize medicine

25 + Phase 2 and phase 3 clinical trials in oncology

Explore late-stage clinical trials

10 + Novel-novel combination trials

Explore combination trials

€ 2.10 bn Investment into R&D in 2025 to address cancer care across indications with high incidence

Explore our diversified pipeline

Stay up to date

Sign up for our email alert for news on our growing pipeline